IUdR/BUdR Cell Cycle Labelling

Not Applicable

Completed

• Conditions: Hematologic Malignancies

• Registration Number: NCT00042250
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Detailed Description

Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.

Study Timeline

• Study Start: 1992-05
• Study First Submitted: 2002-07-24
• Study First Submitted QC: 2002-07-25
• Study First Posted: 2002-07-26
• Primary Completion: 2002-10
• Study Completion: 2002-10
• Status Verified: 2012-01
• Last Update Submitted: 2012-01-20
• Last Update Posted: 2012-01-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

M.D. Anderson Cancer Center; 🇺🇸 Houston, Texas, United States